Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2006Biological Chemistry

The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction

View Full Paper
Ask AI
Bookmark
Share

Key result

Tissue kallikrein protects against oxidative damage in cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction in experimental animal models.

Why the study?

Does the tissue kallikrein-kinin system protect against cardiovascular and renal diseases and ischemic stroke?

Population

Experimental animal models and humans with hypertension, cardiovascular and renal diseases

Design

Review

Authors

JCJulie ChaoGBGrant BledsoeHYHang Yin

Discussion

Loading...

Member takes

Overview

Hypothesis-generating in animal models; leaves open human trials to test tissue kallikrein-kinin system as therapeutic target.

Structured PICO

Does the tissue kallikrein-kinin system protect against cardiovascular and renal diseases and ischemic stroke?

P
Population
Experimental animal models (transgenic mice/rats, hypertensive rat models) and humans with hypertension, cardiovascular and renal diseases
I
Intervention
Kallikrein gene delivery or kallikrein protein infusion
O
Outcome
Cardiac, renal and neurological function

The tissue kallikrein-kinin system represents a potential novel therapeutic target for the prevention and treatment of heart failure, renal disease, and stroke.

Cite This Study

Chao et al. (2006) conducted a review in Cardiovascular and renal diseases, ischemic stroke. Tissue kallikrein/kinin system was evaluated. Tissue kallikrein protects against oxidative damage in cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction in experimental animal models.

synapsesocial.com/papers/6a71cf8575498292b70b2819https://doi.org/10.1515/bc.2006.085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kallistatin is a potent new vasodilator.1997 · 93 citations
  2. 2Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans2005 · 67 citations
  3. 3THE URINARY EXCRETION OF A DEPRESSOR SUBSTANCE (KALLIKREIN OF FREY AND KRAUT) IN ARTERIAL HYPERTENSION*1934 · 139 citations
  4. 4Tissue-specific expression of kallikrein-related genes in the rat1985 · 94 citations
  5. 5Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats2001 · 86 citations